ArticleJTCVS open2026
Biogenic polymer-based heart valve for congenital cardiac surgery.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current heart valve prostheses in congenital cardiac surgery (CCS) are unable to grow, remodel, or adapt to a child's evolving physiology, resulting in increased mortality rates due to material-related limitations. The excellent biocompatibility and hemocompatibility of bacterial cellulose (BC) make it a promising alternative. This study aimed to use BC to develop a biogenic polymer-based heart valve and then to assess its hemodynamic performance and long-term durability. Methods: Heart valve leaflets were produced via a standard BC protocol and compressed to a minimal thickness, and their biomechanical properties were evaluated. Using a customized template, BC leaflets were sutured into a 23-mm stent scaffold. Two prototype series with different leaflet designs were tested in a mock circulatory flow loop model with a flow rate of 5 L/minute at 120/80 mm Hg. Long-term durability was assessed for 10 ± 0.5 million cycles at 120/80 mm Hg, followed by retesting. Results: BC valve leaflets exhibited a thickness reduction of 94.01% to 0.3 ± 0.11 mm ( Conclusions: The potential of BC for use in CCS was demonstrated by developing a new biogenic polymer-based valve with excellent hemodynamic performance. These results warrant further investigation and development of this biomaterial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.